EUVIMEDEUVIMED entdecken
Crossref

Development of Novel Indazolyl‐Acyl Hydrazones as Antioxidant and Anticancer Agents that Target VEGFR‐2 in Human Breast Cancer Cells

Sindhu M Parameshwaraiah, Rashmi Shivakumar, Zhang Xi, Tejaswini P Siddappa, Akshay Ravish, Arunkumar Mohan, Lisha K Poonacha, Pradeep M Uppar, Shreeja Basappa, Dukanya Dukanya, Santhosh L Gaonkar, Kempaiah Kemparaju und 3 weitere

Chemistry & Biodiversity · 2024-03 · 21 (3)

DOI: 10.1002/cbdv.202301950 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 27.02.2024. Verfasst von Sindhu M Parameshwaraiah und 14 weiteren Autor:innen. Beteiligte Einrichtung: University of Mysore, Manasagangotri, Laboratory of Chemical Biology, Department of Studies in Organic Chemistry, Mysore, 570006, India. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Vision Group on Science and Technology (CESEM), Government of Karnataka, Singapore MOE Tier 1.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increased expression of VEGFR‐2 in a variety of cancer cells promotes a cascade of cellular responses that improve cell survival, growth, and proliferation. Heterocycles are common structural elements in medicinal chemistry and commercially available medications that target several biological pathways and induce cell death in cancer cells. Herein, the evaluation of indazolyl‐acyl hydrazones as antioxidant and anticancer agents is reported. Compounds 4e and 4j showed inhibitory activity in free radical scavenging assays (DPPH and FRPA). The titled compounds were employed in cell viability studies using MCF‐7 cells, and it was observed that compounds 4f and 4j exhibited IC 50 values 15.83 μM and 5.72 μM, respectively. In silico docking revealed the favorable binding energies of ‐7.30 kcal/mol and ‐8.04 kcal/mol for these compounds towards Vascular Endothelial Growth Factor Receptor‐2 (VEGFR‐2), respectively. In conclusion, compounds with antioxidant activity and that target VEGFR‐2 in breast cancer cells are reported.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic AgentsHumansFemaleMolecular StructureStructure-Activity RelationshipAntioxidantsVascular Endothelial Growth Factor Receptor-2HydrazonesVascular Endothelial Growth Factor ACell ProliferationDrug DesignMolecular Docking SimulationDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

Acyl hydrazonesAnticancerAntioxidantAutodockIndazole

Substanzen

AntioxidantsVascular Endothelial Growth Factor Receptor-2HydrazonesVascular Endothelial Growth Factor AAntineoplastic Agents

Autor:innen und Institutionen

  • University of Mysore, Manasagangotri, Laboratory of Chemical Biology, Department of Studies in Organic Chemistry, Mysore, 570006, India.
  • Shenzhen Bay Laboratory, Shenzhen, 518055, China.
  • Department of Chemistry, BITS-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, 500078, India.
  • Manipal Academy of Higher Education, Department of Chemistry, Manipal Institute of Technology, Manipal, 576104, India.
  • University of Mysore, Manasagangotri, Department of Studies in Biochemistry, Mysore, 570006, India.
  • Tsinghua University, Tsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Shenzhen, 518055, China.

ORCID-Profile: Basappa Basappa

Förderung

  • Vision Group on Science and Technology (CESEM)
  • Government of Karnataka
  • Singapore MOE Tier 1
  • National Research Foundation of Korea (NRF)
  • Korean government (MSIP)
  • National Natural Science Foundation of China
  • Shenzhen Key Laboratory of Innovative Oncotherapeutics
  • Universities Stable Funding Key Projects

Zitieren

APA

Parameshwaraiah, S. M., Shivakumar, R., Xi, Z., Siddappa, T. P., Ravish, A., Mohan, A., Poonacha, L. K., Uppar, P. M., Basappa, S., Dukanya, D., Gaonkar, S. L., Kemparaju, K., Lobie, P. E., Pandey, V., & Basappa, B. (2024). Development of Novel Indazolyl‐Acyl Hydrazones as Antioxidant and Anticancer Agents that Target VEGFR‐2 in Human Breast Cancer Cells. Chemistry & Biodiversity, 21(3). https://doi.org/10.1002/cbdv.202301950

Vancouver

Parameshwaraiah SM, Shivakumar R, Xi Z, Siddappa TP, Ravish A, Mohan A, et al. Development of Novel Indazolyl‐Acyl Hydrazones as Antioxidant and Anticancer Agents that Target VEGFR‐2 in Human Breast Cancer Cells. Chemistry & Biodiversity. 2024;21(3). doi:10.1002/cbdv.202301950

BibTeX
@article{Parameshwaraiah2024,
  author = {Parameshwaraiah, Sindhu M and Shivakumar, Rashmi and Xi, Zhang and Siddappa, Tejaswini P and Ravish, Akshay and Mohan, Arunkumar and Poonacha, Lisha K and Uppar, Pradeep M and Basappa, Shreeja and Dukanya, Dukanya and Gaonkar, Santhosh L and Kemparaju, Kempaiah and Lobie, Peter E and Pandey, Vijay and Basappa, Basappa},
  title = {Development of Novel Indazolyl‐Acyl Hydrazones as Antioxidant and Anticancer Agents that Target VEGFR‐2 in Human Breast Cancer Cells},
  journal = {Chemistry & Biodiversity},
  year = {2024},
  volume = {21},
  number = {3},
  doi = {10.1002/cbdv.202301950}
}
Kostenlos starten →